CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma

Chemokines play a key role in orchestrating the recruitment and positioning of myeloid cells within the tumor microenvironment. However, the tropism regulation and functions of these cells in hepatocellular carcinoma (HCC) are not completely understood. Herein, by scrutinizing the expression of all chemokines in HCC cell lines and tissues, we found that CCL15 was the most abundantly expressed chemokine in human HCC. Further analyses showed that CCL15 expression was regulated by genetic, epigenetic, and microenvironmental factors, and negatively correlated with patient clinical outcome. In addition to promoting tumor invasion in an autocrine manner, CCL15 specifically recruited CCR1+ cells toward HCC invasive margin, approximately 80% of which were CD14+ monocytes. Clinically, a high density of marginal CCR1+CD14+ monocytes positively correlated with CCL15 expression and was an independent index for dismal survival. Functionally, these tumor‐educated monocytes directly accelerated tumor invasion and metastasis through bursting various pro‐tumor factors and activating signal transducer and activator of transcription 1/3, extracellular signal‐regulated kinase 1/2, and v‐akt murine thymoma viral oncogene homolog signaling in HCC cells. Meanwhile, tumor‐derived CCR1+CD14+ monocytes expressed significantly higher levels of programmed cell death‐ligand 1, B7‐H3, and T‐cell immunoglobulin domain and mucin domain‐3 that may lead to immune suppression. Transcriptome sequencing confirmed that tumor‐infiltrating CCR1+CD14+ monocytes were reprogrammed to upregulate immune checkpoints, immune tolerogenic metabolic enzymes (indoleamine and arginase), inflammatory/pro‐angiogenic cytokines, matrix remodeling proteases, and inflammatory chemokines. Orthotopic animal models confirmed that CCL15‐CCR1 axis forested an inflammatory microenvironment enriched with CCR1+ monocytes and led to increased metastatic potential of HCC cells. Conclusion: A complex tumor‐promoting inflammatory microenvironment was shaped by CCL15‐CCR1 axis in human HCC. Blockade of CCL15‐CCR1 axis in HCC could be an effective anticancer therapy.

[1]  W. Hassan,et al.  Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma , 2017, Cytokine.

[2]  U. Grohmann,et al.  The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. , 2017, Current opinion in pharmacology.

[3]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[4]  A. Jemal,et al.  Disparities in liver cancer occurrence in the United States by race/ethnicity and state , 2017, CA: a cancer journal for clinicians.

[5]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[6]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[7]  Y. Zhuang,et al.  Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway , 2017, Gut.

[8]  D. Saul,et al.  The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia , 2017, Leukemia.

[9]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[10]  S. Qiu,et al.  CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis , 2016, Oncotarget.

[11]  D. Kuang,et al.  Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma , 2016, Nature communications.

[12]  I. Ng,et al.  Hypoxia induces myeloid‐derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C‐C motif) ligand 26 , 2016, Hepatology.

[13]  D. Kuang,et al.  Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization. , 2016, Cancer discovery.

[14]  H. Date,et al.  Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis , 2016, Clinical Cancer Research.

[15]  Ya Cao,et al.  Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. , 2016, Gastroenterology.

[16]  Ya Cao,et al.  miR‐28‐5p‐IL‐34‐macrophage feedback loop modulates hepatocellular carcinoma metastasis , 2016, Hepatology.

[17]  Peng Zhang,et al.  CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma , 2016, Hepatology International.

[18]  Xuehao Wang,et al.  Chemokine CCL15 Mediates Migration of Human Bone Marrow‐Derived Mesenchymal Stem Cells Toward Hepatocellular Carcinoma , 2016, Stem cells.

[19]  Yukio Fujiwara,et al.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.

[20]  Jing Wu,et al.  CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion , 2016, Tumor Biology.

[21]  Jing-quan Li,et al.  Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma , 2015, Gut.

[22]  T. Welling,et al.  Myeloid cells in hepatocellular carcinoma , 2015, Hepatology.

[23]  M. Taketo,et al.  Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15–CCR1 Chemokine Axis , 2015, Clinical Cancer Research.

[24]  Dmitri D. Pervouchine,et al.  The human transcriptome across tissues and individuals , 2015, Science.

[25]  M. Mason,et al.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer , 2014, Oncoimmunology.

[26]  F. Tacke,et al.  Roles for chemokines in liver disease. , 2014, Gastroenterology.

[27]  G. Giannelli,et al.  Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment , 2014, Gut.

[28]  E. Hatano,et al.  Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. , 2013, Gastroenterology.

[29]  S. Qiu,et al.  Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[30]  L. McShane,et al.  Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  H. Guo,et al.  Identification of serum CCL15 in hepatocellular carcinoma , 2013, British Journal of Cancer.

[32]  T. Greten,et al.  Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma , 2012, Digestive Diseases.

[33]  Xianghuo He,et al.  CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. , 2012, Cancer research.

[34]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[35]  Q. Hamid,et al.  Expression and regulation of CCL15 by human airway smooth muscle cells , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  S. Qiu,et al.  Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. , 2011, Journal of hepatology.

[37]  D. Kuang,et al.  Tumor-Activated Monocytes Promote Expansion of IL-17–Producing CD8+ T Cells in Hepatocellular Carcinoma Patients , 2010, The Journal of Immunology.

[38]  Minshan Chen,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells , 2010, Hepatology.

[39]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[40]  Zhao-You Tang,et al.  Downregulation of CCR1 inhibits human hepatocellular carcinoma cell invasion. , 2007, Biochemical and biophysical research communications.

[41]  X. Wang,et al.  The role of cytokines in hepatocellular carcinoma , 2006, Journal of leukocyte biology.

[42]  Yan Li,et al.  Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics , 2004, Journal of Cancer Research and Clinical Oncology.

[43]  Ji Su Kim,et al.  Expression patterns of cytokines and chemokines genes in human hepatoma cells. , 2002, Yonsei medical journal.